PTC Inc. (PTC)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Why PTC Inc. (PTC) Could Beat Earnings Estimates Again
PTC Inc. (PTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC: A Bullish Bet With ServiceMax Integration Boost
PTC Inc. provides lifecycle management software and services globally. The global PLM market is expected to grow at a CAGR of 8.6% from 2022 to 2030, with PTC competing with major industry players. PTC has shown revenue and earnings growth, and strong free cash flow.
Bronstein, Gewirtz and Grossman, LLC sends a Class Action Lawsuit reminder to shareholder investors for PTC Therapeutics, Inc to Lead the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC Stock Surges 30% in a Year: Will the Momentum Continue?
PTC's performance gains from solid momentum across the PLM and CAD business segments.
3 Robotics Stocks That Could Make Your Grandchildren Rich
The best robotics stocks to buy are those that will continue to attract investors who are trying to future-proof their portfolios. That's because the market could to grow 15.91% from $45.85 billion in 2024 to $95.93 billion in 2029.
1 Long-Term Growth Stock to Buy Hand Over Fist and 1 to Avoid
Automation is the future of manufacturing, and this company has a bright future, but its management needs to restore confidence in its guidance. This industrial software provider is about to start generating some serious cash flow.
PTC Inc. (PTC) Up 1.9% Since Last Earnings Report: Can It Continue?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
PTC Stock Surges 41% in a Year: Will the Rally Continue?
PTC's performance gains from solid momentum across the PLM and CAD business segments.
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
PTC stock hit a nine-month high Monday after the European Commission decided against pulling its drug, Translarna, from the market. Translarna has a conditional approval in Europe to treat patients with a muscle-wasting disease known as Duchenne muscular dystrophy, or DMD. Twice — in September and January — the Committee for Medicinal Products for Human Use issued a negative opinion on the PTC Therapeutics (PTCT) drug. But following what PTC previously called "tremendous outcry from the patient and physician community," the European Commission has asked its committee to reexamine its opinion. And, so, "Translarna lives to fight another day," Leerink Partners analyst Joseph Schwartz said in a report to clients. It's rare for the European Commission to not adopt its committee's opinion, RBC Capital Markets analyst Brian Abrahams said in a client note. The news Monday increases the chances Translarna remains on the market in Europe and other jurisdictions, he said. But U.S. approval is still a wild card. "We believe the recent delay in EC action had made this outcome increasingly likely," he said. We "view this as a positive development, as it should improve cash flows, reduce capital raise needs and increase floor valuation into (Huntington's disease) data and (phenylketonuria) launch." On today's stock market, PTC stock rocketed 21.2% to 40.12. Shares launched into a profit-taking zone after breaking out of a cup base with a buy point at 32.91 earlier this month, according to MarketSurge. Following the European Commission's decision, PTC Therapeutics paused its guidance for 2024. The firm said it can't accurately forecast whether Translarna will remain on the market in Europe. But RBC's Abrahams says precedent suggests it will. The European Commission and CHMP had a similar back-and-forth over Uniqure's (QURE) now defunct gene therapy, Glybera. Glybera stayed on the market in Europe until Uniqure withdrew it due to commercial struggles in 2017. Abrahams kept his sector perform rating on PTC stock, but raised his price target to 39 from 29. He says the European Commission's decision wasn't a surprise given appeals from patients and doctors. Schwartz, the Leerink analyst, offered a similar view. "We generally see the European Medicines Agency as less easily influenced by patient advocacy groups than the Food and Drug Administration, but as we have noted in the past, DMD patient groups and DMD parents have a great deal of influence and shouldn't be discounted in the drug review and approval process," he said. He retained his market perform rating on PTC stock. Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin. YOU MAY ALSO LIKE: The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside? Get Timely Buy & Sell Alerts With IBD Leaderboard IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks Learn How To Time The Market With IBD's ETF Market Strategy
